Skip to main content

A novel approach of organ preservation using anti-necrosis agent before transplantation.

Project description

A simple suppressor of cell death could prolong donor organ viability for transplants

Donated blood can be refrigerated and stored for weeks but donated organs are another story. These complex 3D tissue systems are nurtured by continuous blood supply in vivo, to deliver oxygen and nutrients and remove waste and toxins. Once removed from their natural environment, necrosis (unprogrammed cell death) can set in. Currently, static cold storage is the standard method for organ preservation. However, prolonged cold storage has negative outcomes and solutions are desperately needed. ELAPHARMA has identified molecular inhibitors of necrosis. Treatment of the donor organ prior to transportation and transplantation enables suppression of necrosis for up to 24 hours, and significantly enhanced viability thereafter. It promises to give new hope to millions of people on wait lists.

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Coordinator

ELA PHARMA LTD
Address
Dultsin St 16/6
6936049 Tel Aviv
Israel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000